Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.

Daniela PuglieseLuisa GuidiGiuseppe PriviteraLorenzo BertaniBarbara TolussoLuigi Giovanni PapparellaSimona MaltintiClara Di MarioSara OnaliLinda CeccarelliGian Lodovico RapacciniFranco ScaldaferriElisa GremeseAntonio GasbarriniFrancesco CostaAlessandro Armuzzi

Published in: Expert opinion on biological therapy (2020)

Switching from infliximab originator to CT-P13 seems safe and effective, without differences in immunogenicity. A temporary reduction of clinical benefit after switching could be potentially explained by a 'nocebo-effect response'.

Keyphrases

end stage renal disease
computed tomography
ejection fraction
newly diagnosed
dual energy
chronic kidney disease
contrast enhanced
randomized controlled trial
systematic review
positron emission tomography
magnetic resonance imaging
ulcerative colitis